Good and bad IRF-1: Role in tumor suppression versus autoimmune disease
✍ Scribed by Dan A. Liebermann; Barbara Hoffman
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- English
- Weight
- 94 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0145-2126
No coin nor oath required. For personal study only.
✦ Synopsis
Role in tumor suppression versus autoimmune disease
Interferon regulatory factor-1 (IRF-1) is the founder member in a family of transcriptional activators of the interferon-b (IFNb) gene. IRF-1 plays a role in terminal differentiation of hematopoietic cells and in the transcriptional activation of a variety of genes that are involved in the regulation of innate and adaptive immune responses. Several lines of research have identified IRF-1 as a tumor suppressor in myelodysplasia as well as other types of cancer. Recent evidence has shown that though high levels of IRF-1 favor increase survival in MDS patients it is associated with a higher probability of manifestation of autoimmune disease. Existence of splice variants of IRF-1 has been documented in MDS and other types of cancer and IRF-1 gene variations have been documented influencing IgE regulation and atopic diseases. Thus, it will be important to determine the role IRF-1 variants play in MDS versus autoimmune disease, since they may provide targets for novel differential therapeutics.